{"entity":{"id":"nct07150949","kind":"trial","name":"Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC","aka":[],"tldr":"A phase 2 trial of fOLFOX (5-FU, leucovorin, oxaliplatin), capecitabine, celecoxib and serplulimab in colorectal cancer, run by Fudan University, now recruiting.","summary":"Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) is a phase 2, randomised interventional study registered as NCT07150949 by Fudan University, with a registry enrolment figure of 138 participants, started 2025-08-28 and due to reach its primary completion in 2027-08-31. Interventions recorded: Long-course radiotherapy; Oxaliplatin; Capecitabine; Celecoxib; Short-course radiotherapy; Serplulimab. Conditions listed: Locally Advanced Rectal Cancer; Neoadjuvant Therapy. Primary outcome: Complete response (CR) rate. Colorectal eligibility wording from the registry: \"Pathologically confirmed rectal adenocarcinoma\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07150949","url":"https://clinicaltrials.gov/study/NCT07150949"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","imrt-igrt","platinum"],"targets":[],"drugs":["folfox","capecitabine","celecoxib","serplulimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07150949","phase":"2","setting":"A Prospective Randomized Phase II Trial of Long-Course Chemoradiotherapy or Short-Course Radiotherapy Combined With CAPOX, PD-1 Antibody, and a COX-2 Inhibitor for Microsatellite Stable Locally Advanced Rectal Cancer (SERRAC)","sponsor":"Fudan University","enrolled":138,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07150949/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"celecoxib","kind":"drug","name":"Celecoxib","route":"/drugs/celecoxib/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}